Never before has the world had such powerful tools to combat HIV. Yet, their deployment has never seemed so fragile. In Rio de Janeiro, the 26th International AIDS Conference, AIDS 2026, concludes on July 31 with a paradox that extends far beyond medicine: treatments, injectable prevention, and surveillance systems are advancing, but a global funding crisis threatens to deprive millions of these advancements.
Held from July 26 to 31 in Brazil, the largest global meeting dedicated to HIV brings together researchers, governments, healthcare providers, donors, and associations. The World Health Organization presents the first mid-term evaluation of global strategies aimed at HIV, viral hepatitis, and sexually transmitted infections by 2030. The central message is brutal: science is advancing, but access remains the true battleground.
A Global Conference at a Moment of Truth
The WHO describes AIDS 2026 as a meeting organized amid an unprecedented funding crisis and significant cuts to budgets dedicated to HIV programs. This alert is not merely a matter of international accounting. A sudden drop in resources can interrupt testing, reduce prevention efforts, close community services, and weaken the supply of antiretroviral medications.
HIV requires continuity. When a person begins treatment, the system must ensure consultations, tests, and medications over time. When this chain is broken, individual risk increases, and public health declines. Progress accumulated over decades can then be lost much more quickly than it was gained.
The Medical Weapon That Changes the Rules
The strongest symbol of this new scientific phase is lenacapavir. This long-acting molecule, already approved by the U.S. Food and Drug Administration for HIV prevention, can be administered as an injection twice a year. It is neither a vaccine nor a curative treatment, but it can reduce a major barrier: the need for daily prevention.
For individuals facing stigma, distance from care centers, high mobility, or adherence difficulties, six months of protection can transform the experience of prevention. The WHO emphasizes that long-acting injectable formulations could change the way prevention medications are utilized. However, their impact will depend on price, national approvals, available volumes, and the capacity of health systems to reach the most exposed populations.
This is precisely where the paradox appears. An innovation may be spectacular in clinical trials but remain marginal if it does not reach the clinics, associations, and areas where new infections occur. The battle against HIV is therefore fought as much in procurement contracts, manufacturing licenses, and public budgets as it is in laboratories.
Why Africa is at the Center of the Equation
Africa bears a significant share of the global HIV burden and remains particularly exposed to external financial shocks. According to UNAIDS, 77% of funding for the African response came from external sources in 2024. This dependence means that a budget decision made in Washington, Brussels, or a major foundation can have almost immediate effects in an African health center.
Signs of rebalancing exist. Twenty-two African countries are working with UNAIDS and its partners on sustainability and transition plans, while eleven have reported an increase in their national budget dedicated to HIV for 2026. The goal is to better integrate services into national health systems and increase domestic funding. However, this transformation cannot be instantaneous: withdrawing aid before the supports are solid would create a dangerous void.
Europe and France Are Not Spectators
The crisis also directly concerns Europe. The movement of people, conflicts, and displacements render any response confined within national borders illusory. In Eastern Europe and Central Asia, UNAIDS reported in February a 34% increase in AIDS-related deaths since 2010. Only about half of people living with HIV there received treatment, and viral suppression, estimated at 42%, remained the lowest in the world.
For France, supporting the global response is therefore both a matter of solidarity, health diplomacy, and collective interest. Contributions to multilateral institutions, the actions of Expertise France, public research, associations, and national screening policies form a continuous continuum. Effective prevention elsewhere reduces infections, late diagnoses, and inequalities everywhere.
Communities: An Irreplaceable Link
AIDS 2026 also reminds us of a lesson often overlooked: medications alone are not enough. Community services reach individuals that traditional structures struggle to engage, especially when fear, discrimination, or criminalization distance them from care. This work includes information, testing, support, distribution of prevention methods, and maintaining treatment.
However, these systems are among the most vulnerable to budget cuts. They often rely on small organizations, short contracts, and fragmented international funding. Eliminating them may seem to produce quick savings, but the cost later manifests as preventable infections, more advanced diseases, and additional pressure on hospitals.
2030 Approaches: What Can Still Change
The year 2030, set to end AIDS as a public health threat, is no longer a distant horizon. Less than four years remain to accelerate testing, secure treatments, disseminate new prevention options, and reduce inequalities. The WHO’s mid-term evaluation should help identify countries and populations left behind, then focus efforts where the gaps are greatest.
Three decisions will be crucial. First, protect essential budgets during the transition to increased national funding. Second, negotiate prices and licenses that allow long-acting innovations to reach low- or middle-income countries. Third, preserve human rights and community organizations, without which the most exposed individuals remain invisible to the system.
A Signal the World Cannot Ignore
Rio sends a signal that is as simple as it is uncomfortable: failure may no longer stem from a lack of scientific knowledge. It could arise from a political and financial choice. The world knows better how to prevent HIV, diagnose it, and treat it. It now has tools capable of alleviating the daily burden of prevention.
But a medical advancement is only historic when it becomes accessible. If budgets contract at the precise moment when science opens new possibilities, AIDS 2026 will be remembered as the meeting where the world glimpsed a possible victory without guaranteeing the means to achieve it. Conversely, protecting funding, diversifying its sources, and lowering the cost of innovations could transform the paradox of Rio into a global turning point.
